Renaissance Technologies LLC grew its position in shares of Albireo Pharma Inc (NASDAQ:ALBO) by 16.2% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 107,366 shares of the biopharmaceutical company’s stock after purchasing an additional 14,934 shares during the quarter. Renaissance Technologies LLC’s holdings in Albireo Pharma were worth $3,811,000 as of its most recent filing with the SEC.
Several other hedge funds have also recently modified their holdings of the business. Northern Trust Corp boosted its holdings in shares of Albireo Pharma by 60.3% during the 1st quarter. Northern Trust Corp now owns 15,766 shares of the biopharmaceutical company’s stock worth $513,000 after buying an additional 5,932 shares in the last quarter. BlackRock Inc. boosted its holdings in shares of Albireo Pharma by 522.4% during the 1st quarter. BlackRock Inc. now owns 76,780 shares of the biopharmaceutical company’s stock worth $2,501,000 after buying an additional 64,444 shares in the last quarter. Element Capital Management LLC bought a new position in shares of Albireo Pharma in the 1st quarter worth $335,000. Millennium Management LLC lifted its holdings in shares of Albireo Pharma by 234.0% in the 1st quarter. Millennium Management LLC now owns 155,611 shares of the biopharmaceutical company’s stock worth $5,068,000 after purchasing an additional 109,017 shares in the last quarter. Finally, Hartwell J M Limited Partnership lifted its holdings in shares of Albireo Pharma by 32.7% in the 2nd quarter. Hartwell J M Limited Partnership now owns 13,400 shares of the biopharmaceutical company’s stock worth $476,000 after purchasing an additional 3,300 shares in the last quarter. 63.41% of the stock is currently owned by institutional investors.
Shares of ALBO opened at $28.36 on Friday. Albireo Pharma Inc has a 12-month low of $21.25 and a 12-month high of $39.87.
Albireo Pharma (NASDAQ:ALBO) last issued its earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($1.22) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.98) by ($0.24). The company had revenue of $0.73 million during the quarter, compared to the consensus estimate of $2.00 million. Equities research analysts anticipate that Albireo Pharma Inc will post -3.39 EPS for the current year.
In other news, insider Ronald Harold Wilfred Cooper bought 788 shares of the business’s stock in a transaction that occurred on Tuesday, August 14th. The shares were bought at an average cost of $31.85 per share, for a total transaction of $25,097.80. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 3.60% of the stock is owned by company insiders.
ALBO has been the topic of a number of recent research reports. BidaskClub upgraded Albireo Pharma from a “sell” rating to a “hold” rating in a report on Saturday, September 1st. Wedbush reiterated an “outperform” rating and issued a $69.00 target price on shares of Albireo Pharma in a report on Tuesday, August 7th. Cowen reiterated a “buy” rating on shares of Albireo Pharma in a report on Wednesday, August 8th. Finally, Zacks Investment Research upgraded Albireo Pharma from a “hold” rating to a “buy” rating and set a $36.00 target price on the stock in a report on Tuesday, July 24th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $59.40.
Albireo Pharma Profile
Albireo Pharma, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI) disorders in the United States. Its lead product candidate includes A4250, an orally administered ileal sodium dependent bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating progressive familial intrahepatic cholestasis and phase II clinical trial for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases.
Recommended Story: Book Value Of Equity Per Share – BVPS Explained
Want to see what other hedge funds are holding ALBO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Albireo Pharma Inc (NASDAQ:ALBO).
Receive News & Ratings for Albireo Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albireo Pharma and related companies with MarketBeat.com's FREE daily email newsletter.